姜提取物用于接受高剂量顺铂患者化疗所致恶心呕吐管理的随机双盲安慰剂对照多中心研究
该随机双盲安慰剂对照多中心研究纳入计划接受≥2个周期高剂量(>50 mg/m2)顺铂化疗的患者,比较姜提取物160 mg/日与安慰剂在标准止吐预防基础上对化疗所致恶心呕吐(CINV)的作用。结果显示两组延迟性、周期间及预期性恶心发生率在第一和第二周期均无差异;姜在女性(P=0.048)和头颈癌患者(P=0.038)的功能性生活指数恶心评分差值上有获益。作者结论认为每日加用姜虽安全,但未对CINV产生保护作用。
要点
- 在高剂量顺铂化疗患者中,每日加用姜提取物160 mg未降低延迟性、周期间及预期性恶心发生率。
- 姜在女性(P=0.048)和头颈癌患者(P=0.038)的功能性生活指数恶心评分差值上显示获益。
- 两组安全性和依从性无差异,但亚组获益需专门研究验证。
核心结论
- 在接受高剂量顺铂治疗的患者中,每日加用姜虽安全,但未对化疗所致恶心呕吐产生保护作用。
- 在女性及头颈癌等恶心高风险亚组中观察到的有利效果值得专门研究。
研究设计与样本
- 随机、双盲、安慰剂对照、多中心研究。
- 纳入计划接受≥2个周期高剂量(>50 mg/m2)顺铂化疗的患者。
- 共121例接受姜提取物160 mg/日(含标准化生物活性成分剂量),123例接受安慰剂,均在标准止吐预防基础上从顺铂给药次日起加用。
- 通过每日视觉模拟评分和功能性生活指数呕吐问卷评估CINV。
- 主要目标为延迟性恶心的保护作用;次要终点包括周期间恶心和预期性恶心症状。
主要发现
- 肺癌(49%)和头颈癌(35%)为最常见肿瘤类型。
- 两组安全性和依从性无差异。
- 第一和第二周期中,延迟性、周期间及预期性恶心发生率在两组间均无差异。
- 功能性生活指数恶心评分差值(第6天减第1天)方面,女性患者中姜优于安慰剂(P=0.048),头颈癌患者中姜优于安慰剂(P=0.038)。
局限性
- 原文指出既往研究存在设计不足、人群异质性、样本量小和受试产品质量差等局限,限制了结果的可推广性。
- 作者结论指出,在女性及头颈癌亚组中观察到的有利效果值得专门研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The activity of ginger in the management of chemotherapy-induced nausea and vomiting (CINV) has been suggested, but design inadequacies, heterogeneity of the population, small numbers and poor quality of tested products limit the possibility to offer generalizable results. PATIENTS AND METHODS: We conducted a randomized, double-blind, placebo-controlled, multicenter study in patients planned to receive ≥2 chemotherapy cycles with high dose (>50 mg/m2) cisplatin. Patients received ginger 160 mg/day (with standardized dose of bioactive compounds) or placebo in addition to the standard antiemetic prophylaxis for CINV, starting from the day after cisplatin administration. CINV was assessed through daily visual-analogue scale and Functional Living Index Emesis questionnaires. The main objective was protection from delayed nausea; secondary end points included intercycle nausea and nausea anticipatory symptoms. RESULTS: In total, 121 patients received ginger and 123 placebo. Lung (49%) and head and neck cancer (HNC; 35%) were the most represented tumors. No differences were reported in terms of safety profile or compliance. The incidence of delayed, intercycle and anticipatory nausea did not differ between the two arms in the first cycle and second cycle. A benefit of ginger over placebo in Functional Living Index Emesis nausea score differences (day 6-day 1) was identified for females (P = 0.048) and HNC patients (P = 0.038). CONCLUSIONS: In patients treated with high-dose cisplatin, the daily addition of ginger, even if safe, did not result in a protective effect on CINV. The favorable effect observed on nausea in subgroups at particular risk of nausea (females; HNC) deserves specific investigation.
引用
- Bossi P, Cortinovis D, Fatigoni S, et al. A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin. Ann Oncol. 2017. PMID: 28666335. doi:10.1093/annonc/mdx315
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。